Join the On-Demand Highlights Meeting at soho.click/highlightsVE.
To enter, just type in your email address.

Digital Agenda

The SOHO Highlights: State of the Art & Next Questions meeting will be held on October 27, 2021 as a virtual event. The “SOHO Highlights” meeting is designed to provide participants with an overview of the latest advances in hematologic malignancies and a preview of where the field is going next. Investigators from around the world will join the meeting for a day of learning and interactive, virtual discussion with the speakers. Each presentation is 25 minutes followed by a 10-minute, live Questions & Answer session with the audience. Note that the Zoom webinar platform will be utilized to facilitate interaction with attendees.

You may view the SOHO Highlights session line-up in the following Digital Agenda. Those that have registered may select the link to join the session directly. Note that all times in the program are listed in Central Daylight Time (CDT) which is 5 hours behind Coordinated Universal Time (UTC -5).

Wednesday, October 27, 2021

Part I

IntroductionHagop Kantarjian - MD Anderson Cancer Center, Houston, Texas, USAHagop Kantarjian View Presentation

Part I

State of the Art & Next Questions: Acute Lymphoblastic LeukemiaElias Jabbour - MD Anderson Cancer Center, Houston, Texas, USAElias Jabbour View Presentation

Part I

State of the Art & Next Questions: Acute Myeloid LeukemiaHagop Kantarjian - MD Anderson Cancer Center, Houston, Texas, USAHagop Kantarjian View Presentation

Part I

State of the Art & Next Questions: Cellular TherapySergio Giralt - Memorial Sloan Kettering Cancer Center, New York, New York, USASergio Giralt View Presentation

Part I

State of the Art & Next Questions: Chronic Lymphocytic LeukemiaJennifer Brown - Dana-Farber Cancer InstituteJennifer Brown View Presentation

Part I

State of the Art & Next Questions: Chronic Myeloid LeukemiaJorge Cortés - Georgia Cancer Center, Augusta, Georgia, USAJorge Cortés View Presentation

Part II

State of the Art & Next Questions: Multiple MyelomaSagar Lonial - Emory University, Winship Cancer InstituteSagar Lonial View Presentation

Part II

State of the Art & Next Questions: Indolent B-Cell LymphomaLaurie Sehn - BC Cancer Agency, Vancouver, CanadaLaurie Sehn View Presentation

Part II

State of the Art & Next Questions: T-Cell LymphomaBarbara Pro - Robert H Lurie Cancer Center, Northwestern UniversityBarbara Pro View Presentation

Part II

State of the Art & Next Questions: Mantle Cell LymphomaBrad Kahl - Washington University School of Medicine in St LouisBrad Kahl View Presentation

Part II

State of the Art & Next Questions: Hodgkin LymphomaCraig Moskowitz - University of Miami Health SystemCraig Moskowitz View Presentation

Part II

State of the Art & Next Questions: Aggressive B-Cell LymphomaGrzegorz Nowakowski - Mayo Clinic Rochester, Rochester, Minnesota, USAGrzegorz Nowakowski View Presentation

Part II

State of the Art & Next Questions: Myelodysplastic SyndromesGuillermo Garcia-Manero - MD Anderson Cancer Center, Houston, Texas, USAGuillermo Garcia-Manero View Presentation

Part II

State of the Art & Next Questions: Myeloproliferative NeoplasmsSrdan Verstovsek - The University of Texas MD Anderson Cancer CenterSrdan Verstovsek View Presentation

Part II

Closing RemarksJennifer Brown - Dana-Farber Cancer InstituteJennifer Brown View Presentation
Time Zone: (UTC-06:00) Central Time (US & Canada) [Change Time Zone]